

Curriculum Vitae
Mark E. Dato, M.D., Ph.D.
markdato@gmail.com

Education/Professional Experience

1977-1981	B.S. (Biology) Loyola University of the South, New Orleans, LA
1981-1991	Ph.D. (1989, Dept. of Microbiology and Immunology) M.D. (1991)University of Health Sciences, The Chicago Medical School North Chicago, Illinois
1991-1994	Resident in Pediatrics, Children's Hospital Medical Center, Cincinnati, Ohio
1994-1997	Fellow, Pediatric Pulmonology, Children's Hospital Medical Center, Cincinnati, Ohio

Work History

1997- 2007	Adjunct Clinical Instructor – Dept of Pulmonary Medicine, Cincinnati Children's Hospital.
1997-1999	Scientist, Clinical Pharmacology and Pharmacokinetics, Procter & Gamble Pharmaceuticals
2000-2005	Section Head, Early Drug Development, Procter and Gamble Pharmaceuticals
2005-2007	Associate Director, Early Drug Development Procter & Gamble Pharmaceuticals
2007–2008	Director, Global Musculoskeletal Category, Procter & Gamble Pharmaceuticals
2009-2010	Director, Statistics, Data Management, Scientific Writing and Clinical, Procter & Gamble
2010 –2012	Director - Product Safety & Regulatory Affairs Global Beauty Care. Procter & Gamble
2012- 2016	Director, Global Quality and Health Complaints Management, Global Product Stewardship GCO, Corporate Function R&D
2016- 2017	Director, Global Technology, PGT Healthcare, Geneva Switzerland
2017-2019	Retired
Current	Chief Scientific/Chief Medical Officer Eikonoklastes Therapeutics, Inc

Boards and Appointments

Publications

- Dato M. and Kim Y.B. Production and characterization of monoclonal antibodies against porcine natural killer cells. *Fed Proc* 1986; 45:1117 .
- Dato M. and Kim Y.B. Characterization and utilization of a monoclonal antibody inhibiting porcine natural killer cell activity for isolation of natural killer cells. *J Immunol* 1990; 144:4452-4462.
- Dato ME, Wierda W.G. and Kim Y.B. A triggering structure recognized by G7 monoclonal antibody on porcine lymphocytes and granulocytes. *Cell Immunol* 1992; 140:468-477.
- Wierda W.G, Johnson B.D., Dato M.E., Kim Y.B. Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex. *Cell Immunol* 1993; 146:270-283.
- Wierda W.G., Johnson, B.D., Dato M.E. and Kim Y.B. Induction of porcine granulocyte-mediated tumor cytotoxicity by two distinct monoclonal antibodies against lytic trigger molecules (PNK-E/G7). *J Immunol* 1993;151:7117-7127.
- M. Dato, contributing author. Exclusion of Objectionable Microorganisms from Nonsterile Pharmaceuticals, Medical Devices and Cosmetics. Parenteral Drug Association, Technical Report 67, 2014

Abstracts

- Dato M. and Kim Y.B. Production and characterization of monoclonal antibodies against porcine natural killer cells. *Proc of the 24th Annual Meeting of the Association of Gnotobiotics*, No. 11.
- Dato M. and Kim Y.B. Characterization and functional analysis of a porcine natural killer inhibitory (PNK-I) monoclonal antibody. *FASEB Journal* 1988; A460 (Abstract No. 954)
- Dato M. and Kim Y.B. Characterization of a monoclonal antibody inhibiting porcine natural killer cell activity (PNK-I). *FASEB Journal* 1989; 3:A816 (Abstract No. 3429).
- Dato M.E, Jones, M.L. and Greenberg, J.M. Cloning and characterization of the promoter region of the murine keratinocyte growth factor (KGF) gene. (*FASEB*, 1997).
- Jones, M.L., M.E. Dato, R. Gendron, H. Wong , J.M. Greenberg. Regulation of KGF/FGF-7 expression in immortalized clonal mouse fetal lung memenchymal cells. (*FASEB*, 1997).

Guler, Hans-Peter, Ann Acheson, Nancy Stambler, Thomas L. Hunt and Mark Dato. First in human study with AXOKINE: A second generation CNTF with potential as a weight loss drug. ENDO 2000 (Abstract # 850508).

McRobie, CL, Buch, AB, Thompson, GA, Dato, ME, Kelly, SC, Agnew, JR, Skuster, JR, and Mitchell, DY Bisoprolol Pharmacokinetics and Pharmacodynamics in Pediatric Subjects, 6 Months to 6 Years of Age. AAPS Pharmsci. 2000; 2(4)

McRobie, CL, Thompson, GA, Dato, ME, Johnson, TD, Seeck, MJ, Russell, DA, Skuster, JR, and Mitchell, DY. Pharmacokinetics of Ziac® (bisoprolol fumarate/hydrochlorothiazide) and Zebeta® (bisoprolol fumarate) in Children, 6 Through 15 Years of Age. AAPS Pharmsci. 2000; 2(4)

Book Chapters

Wilmott, Robert and M. Dato. 1996. Respiratory Diseases. In *Rudolph's Fundamentals of Pediatrics*, eds. A.M. Rudolph and R.K. Kamei. Appleton and Lange, Stanford, CT. 2nd ed.

Wilmott, Robert, B. Chini and M. Dato. 2000. Respiratory Diseases. In *Rudolph's Fundamentals of Pediatrics*, eds. A.M. Rudolph and R.K. Kamei. Appleton and Lange, Stanford, CT. 3rd ed.